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L e t t e r s t o t h e E d i t o r
18F-FDG PET for Routine Posttreatment
Surveillance in Oral and Oropharyngeal
Squamous Cell Carcinoma
TO THE EDITOR: We read with great interest the recent article
by Krabbe et al. (1), in which the authors prospectively evaluated
the impact and timing of 18F-FDG PET for posttreatment
surveillance of oral and oropharyngeal squamous cell cancer.
Forty-eight patients were included after completing their initial
therapy with curative intent.
The patients underwent clinical follow-up and 18F-FDG PET at
3, 6, 9, and 12 mo after initial treatment. Two nuclear medicine
physicians evaluated the PET scans and were unaware of the
findings of the current clinical follow-up. At the second, third, and
fourth PET scans, the nuclear medicine physicians had access to
all available clinical data at the time of the previous scans,
including the results of the previous regular follow-up and of
morphologic imaging but not of the regular follow-up at the time
of the current scan. The PET findings were validated by
histopathology or clinical follow-up and by imaging at 18 mo
after initial treatment.
When 3- and 6-mo posttherapy results were combined, 18F-
FDG PET was found to have detected malignancy in 16 of the 18
patients in whom locoregional recurrences, distant metastases, or
a second primary tumor had occurred. It is therefore no surprise
that the clinical impact of 18F-FDG PET is best between 3
and 6 mo after treatment. The authors demonstrated that the
sensitivity, specificity, and accuracy of 18F-FDG PET were
irrespective of the timing of 18F-FDG PET and had ranges of
93%2100%, 68%276%, and 71%279%, respectively, during the
4 PET scans (Table 6 of the article). The negative predictive value
showed little change between the 4 PET scans, whereas the
positive predictive value was overall higher at the 3- and 6-mo
scans than at 9 and 12 mo after treatment (61% and 47% vs. 29%
and 36%). These findings were surprising to us. We thought that
the diagnostic accuracy and particularly the positive predictive
value of 18F-FDG PET scans should have been higher at 9 and
12 mo than at 3 and 6 mo because more clinical follow-up and
radiographic results after previous PET scans were available for
correlation. The results of previous clinical examinations and
radiographic imaging after the PET scans at 3 or 6 mo after
treatment would help improve the confidence and the accuracy of
the later PET scan interpretations at 9 or 12 mo after treatment.
The general impression is that, between the end of therapy and
PET, there is a decline in false-positive rates that is associated
with an increase in positive predictive values and diagnostic
accuracy (2,3). The results of the current study, however, appear to
be at variance with the general impression. The authors
acknowledged that 18F-FDG PET/CT was shown to have high
accuracy at 12 mo after treatment, but they did not discuss the
findings based on 18F-FDG PET (without CT). We would
appreciate a discussion by the authors in this regard.
We noticed that a considerable percentage (50%) of the false-
positive findings either were due to mucositis (8/40, or 20%) or were
of unknown anatomic substrate (12/40, or 30%). These findings,
however, were not correlated with time of occurrence; thus, the
readers could not appreciate the 18F-FDG PET pattern of these false-
positive findings. Further characterization of these pitfalls of 18F-
FDG PET might help identify and decrease the false-positive rates.
We would appreciate information from the authors in this regard.
A false-positive finding was shown in Figure 2 that apparently
was present in all 4 serial PET scans. Only images of the PET
scans at 3 and 12 mo after therapy were shown, and the authors
did not provide any clinical information on the location of the 18F-
FDG focus that turned out to be false-positive. On the basis of
soft-tissue loss seen in the presented radiographic images of the
figure, we assumed that the patient had a left tonsillar cancer. We
also assumed that the false-positive finding was in the right
tonsillar fossa. On the basis of these assumptions, the right
tonsillar 18F-FDG uptake was most likely physiologic, because
bilateral tonsillar cancer is rare (4). Moreover, if the clinical
examinations and neck CT and MRI findings were not suggestive
of tumor, the 18F-FDG uptake in the right tonsillar fossa should
have been interpreted as physiologic in the 6-, 9-, and 12-mo
scans. We would appreciate the authors’ comments on this specific
case, with inclusion of the neck images of the 4 serial PET scans.
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REPLY: We would like to thank Nguyen and colleagues for their
letter and the 3 questions they have raised after reading our paper
(1): first, why the positive predictive value is higher at the 3- and
6-mo scans than at 9 and 12 mo; second, how the false-positive
findings relate to the time of occurrence; and third, what clinical
information we can present about the false-positive finding
illustrated in Figure 2 of our paper.
Regarding the first question, we described a decline in positive
predictive value during the 4 PET scans. The general impressionCOPYRIGHT ª 2010 by the Society of Nuclear Medicine, Inc.
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